Liver S9 fraction-derived metabolites of curcumin analogue UBS109

ACS Medicinal Chemistry Letters

Volumn 5, Issue 4, 2014, Pages 288-292

  Moore, Terry W ^a,d   Zhu, Shijun ^b   Randolph, Ryan ^c   Shoji, Mamoru ^b   Snyder, James P ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Scynexis Inc   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

curcumin; Curcumin analogue; liver S9 fraction; metabolism; UBS109

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; DRUG METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UBS 109; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CARCINOMA CELL; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; EXPERIMENTAL DOG; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IN VITRO STUDY; LIVER MICROSOME; MACACA FASCICULARIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TISSUE DISTRIBUTION; TOXICITY TESTING;

EID: 84898040148     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4002453     Document Type: Article

References (25)

1. Adams, B. K.; Ferstl, E. M.; Davis, M. C.; Herold, M.; Kurtkaya, S.; Camalier, R. F.; Hollingshead, M. G.; Kaur, G.; Sausville, E. A.; Rickles, F. R.; Snyder, J. P.; Liotta, D. C.; Shoji, M. Synthesis and biological evaluation of novel curcumin analogs as anticancer and antiangiogenesis agents Bioorg. Med. Chem. 2004, 12, 3871-3883
2. Adams, B. K.; Cai, J.; Armstrong, J.; Herold, M.; Lu, Y. J.; Sun, A.; Snyder, J. P.; Liotta, D. C.; Jones, D. P.; Shoji, M. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism Anti-Cancer Drugs 2005, 16, 263-275
3. Subramaniam, D.; May, R.; Sureban, S. M.; Lee, K. B.; George, R.; Kuppusamy, P.; Ramanujam, R. P.; Hideg, K.; Dieckgraefe, B. K.; Houchen, C. W.; Anant, S. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity Cancer Res. 2008, 68, 1962-1969
4. Kasinski, A. L.; Du, Y.; Thomas, S. L.; Zhao, J.; Sun, S.-Y.; Khuri, F. R.; Wang, C.-W.; Shoji, M.; Sun, A.; Snyder, J. P.; Liotta, D. C.; Fu, H. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin Mol. Pharmacol. 2008, 74, 654-661
5. Brown, A.; Shi, Q.; Moore, T. W.; Younghyoun, Y.; Prussia, A.; Maddox, C.; Liotta, D. D.; Shim, H.; Snyder, J. P. Monocarbonyl curcumin analogs: Heterocyclic pleiotropic kinase inhibitors that mediate anti-cancer properties J. Med. Chem. 2013, 56, 3456-3466
6. Olivera, A.; Moore, T. W.; Sun, A.; Liotta, D. C.; Snyder, J. P.; Shim, H.; Marcus, A. I.; Miller, A. H.; Pace, T. W. W. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-bis(2-pyridinylmethylidene)-4- piperidone (EF31): anti-inflammatory and anti-cancer properties Int. Immunopharmacol. 2012, 12, 368-377
7. Zhu, S.; Moore, T. W.; Lin, X.; Morii, N.; Mancini, A.; Howard, R. B.; Culver, D.; Arrendale, R. F.; Reddy, P.; Evers, T. J.; Zhang, H.; Sica, G.; Chen, Z. G.; Sun, A.; Fu, H.; Khuri, F. R.; Shin, D. M.; Snyder, J. P.; Shoji, M. Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts Integr. Biol. 2012, 4, 633-640
8. Zhu, S.; Moore, T. W.; Morii, N.; Howard, R. B.; Culver, D.; Arrendale, R. F.; Reddy, P.; Evers, T. J.; Zhang, H.; Chen, S. G.; Sun, A.; Fu, H.; Khuri, F. R.; Shin, D. M.; Snyder, J. P.; Shoji, M. Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts. Submitted.
9. Yamaguchi, M.; Moore, T. W.; Sun, A.; Snyder, J. P.; Shoji, M. Novel curcumin analogue UBS 109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition Integr. Biol. 2012, 4, 905-913
10. Wu, W.-N.; McKown, L. A. Chapter 11: In vitro drug metabolite profiling using hepatic S9 and human liver microsomes. In Optimization in Drug Discovery: In Vitro Methods (Methods in Pharmacology and Toxicology); Yan, Z.; Cadwell, G. W., Eds.; Humana Press: Totowa, NJ, 2004; pp 163-184.
11. Sugiura, M.; Sato, M.; Kotani, S.; Nakajima, M. Lewis base-catalyzed conjugate reduction and reductive aldol reaction of α,β-unsaturated ketones using trichlorosilane Chem. Commun. 2008, 4309-4311
12. Modzelewska, A.; Pettit, C.; Achanta, G.; Davidson, N. E.; Huang, P.; Khan, S. R. Anticancer activities of novel chalcone and bis-chalcone derivatives Bioorg. Med. Chem. 2006, 14, 3491-3495
13. Reid, J. M.; Buhrow, S. A.; Gilbert, J. A.; Jia, L.; Shoji, M.; Snyder, J. P.; Ames, M. M. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidione,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993). Cancer Chemother. Pharmacol. In press.
14. Lindstrom, T. D.; Whitaker, G. W. Alpha, beta-ketoalkene reduction. A novel reduction pathway in mammalian tissues Drug Metab. Dispos. 1984, 12, 72-76
15. Lindstrom, T. D.; Whitaker, G. W. Saturation of an alpha, beta-unsaturated ketone: a novel xenobiotic biotransformation in mammals Xenobiotica 1984, 14, 503-508
16. Gerhards, E.; Hecker, W.; Hitze, H.; Nieuweboer, B.; Bellmann, O. The metabolism of norethisterone (17-ethinyl-4-estren-17 -ol-3-one) and of dl-and d -norgestrel (18-methyl-17-ethinyl-4-estren-17-ol-3-one) in man Acta Endrocrinol. 1971, 68, 219-248
17. Ireson, C.; Orr, S.; Jones, D. J. L.; Verschoyle, R.; Lim, C.-L.; Luo, J.-L.; Howells, L.; Plummer, S.; Jukes, R.; Williams, M.; Steward, W. P.; Gescher, A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production Cancer Res. 2001, 61, 1058-1064
18. Hoehle, S. I.; Pfeiffer, E.; Sólyom, A.; Metzler, M. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver J. Agric. Food Chem. 2006, 54, 756-764
19. Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B. B. Bioavailability of curcumin: Problems and promises Mol. Pharmaceutics 2007, 4, 807-818
20. Marczylo, T. H.; Steward, W. P.; Gescher, A. J. Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel ultraperformance liquid chromatography (UPLC) method J. Agric. Food Chem. 2009, 57, 797-803
21. Dimmock, R. R.; Hamon, N. W.; Hindmarsh, K. W.; Sellar, A. P.; Turner, W. A.; Rank, G. H.; Robertson, A. J. Evaluation of 2-benzylidenecyclohexanones and 2,6-bis(benzylidene)cyclohexanones for antitumor and cytotoxic activity and as inhibitors of mitochondrial function in yeast: metabolism studies of (E)-2-benyzlidenecyclohexanone J. Pharm. Sci. 1976, 65, 538-543
22. Shim, J. S.; Kim, D. H.; Jung, H. J.; Kim, J. H.; Lim, D.; Lee, S. K.; Kim, K. W.; Ahn, J. W.; Yoo, J. S.; Rho, J. R.; Shin, J.; Kwon, H. J. Hydrazinocurcumin, a novel synthetic curcumin derivative is a potent inhibitor of endothelial cell proliferation Bioorg. Med. Chem. 2002, 10, 2987-2992
23. Simoni, D.; Rizzi, M.; Rondanin, R.; Baruchello, R.; Marchetti, P.; Invidiata, F. P.; Labbozzetta, M.; Poma, P.; Carina, V.; Notarbartolo, M.; Alaimoc, A.; Alessandro, N. D. Antitumor effects of curcumin and structurally β-diketone modified analogs on multidrug resistant cancer cells Bioorg. Med. Chem. Lett. 2008, 18, 845-849
24. Sun, A.; Lu, Y. J.; Hu, H.; Shoji, M.; Liotta, D. C.; Snyder, J. P. Curcumin analog cytotoxicity against breast cancer cells: Exploitation of a redox-dependent mechanism Bioorg. Med. Chem. Lett. 2009, 19, 6627-6631
25. Evers, T.; Reddy, P.; Moore, T. W.; Snyder, J. P.; Arrendale, R. F. Emory Institute for Drug Discovery. Unpublished.